1. Home
  2. Approved trials
  3. » فارسی

A randomized, open label, single dose, crossover, bioequivalence study of Ticagrelor 90mg tablet of Actover Co., IRAN and Brilique 90mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition

Protocol summary

Study aim
A randomized, open label, single dose, crossover, bioequivalence study of Ticagrelor 90mg tablet of Actover Co., IRAN and Brilique 90mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition
Design
A randomized, open label, single dose, crossover, bioequivalence study in 24 healthy subjects under fasting condition
Settings and conduct
This study is carried out in Core Research Center of Zahedan University of Medical Sciences located in Imam Ali Hospital in Zahedan. There is a separate space for sampling and forecasting emergency situations in order to accommodate and rest the volunteers. This crossover and open label study was performed on 24 healthy volunteers. The volunteers' health is verified by the project physician prior to entry into the study, and the volunteers' status is regularly monitored by the project physician on the day of drug administration. This study will be covered by insurance in order to compensate for any adverse effects.
Participants/Inclusion and exclusion criteria
Main Inclusion criteria: Healthy subjects aged between 18 -50 years old and weighed between 50 – 100 kg; Main exclusion criteria: Clinically relevant deviations from normal; Donation a unit of blood or participated in another clinical trial within the last two months; History of drug or alcohol abuse; Used any medication within 7- 14 days before the first treatment
Intervention groups
Intervention: Ticagrelor 90mg tablet, produced by Actover Co., (IRAN), single dose. Control: Brilique 90mg tablet, produced by Astra-Zeneca company, single dose
Main outcome variables
Plasma concentration of Ticagrelor and its active metabolite, AR-C124910XX in plasma at 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20190706044111N28
Registration date: 2022-08-27, 1401/06/05
Registration timing: registered_while_recruiting

Last update: 2022-08-27, 1401/06/05
Update count: 0
Registration date
2022-08-27, 1401/06/05
Registrant information
Name
Ladan Tayebi
Name of organization / entity
Pars Biopharmacy Research Co.
Country
Iran (Islamic Republic of)
Phone
+98 21 8895 6061
Email address
l.tayebi@parsbiopharmacy.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-08-23, 1401/06/01
Expected recruitment end date
2023-08-23, 1402/06/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
A randomized, open label, single dose, crossover, bioequivalence study of Ticagrelor 90mg tablet of Actover Co., IRAN and Brilique 90mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition
Public title
Bioequivalence study of Ticagrelor 90mg tablet of Actover Co., IRAN
Purpose
Other
Inclusion/Exclusion criteria
Inclusion criteria:
Aged between 18 - 50 years Body weight between 50 – 100 kg Having good health on the basis of medical history and physical & clinical examination Understand the procedures and give written informed consent
Exclusion criteria:
Subject had undergone surgery of the gastro-intestinal tract Subject had donated a unit of blood or participated in another clinical trial, within the last two months before the first treatment. Subject had a history of drug or alcohol abuse. Subject who smokes more than 10 cigarettes per day. Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.
Age
From 18 years old to 50 years old
Gender
Both
Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: 24
More than 1 sample in each individual
Number of samples in each individual: 2
Each volunteer, 2 times take medicine in the study. One-time test product and the other time reference product with at least one week wash-out period.
Randomization (investigator's opinion)
Randomized
Randomization description
Using Excel software, each subject will be randomly assigned to one of the two sequence AB or BA in a balanced manner.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Zahedan University of medical Sciences
Street address
Dr. Hessabi square Zahedan University of Medical Sciences
City
Zahedan
Province
Sistan-va-Balouchestan
Postal code
9816743463
Approval date
2022-07-24, 1401/05/02
Ethics committee reference number
IR.ZAUMS.REC.1401.136

Health conditions studied

1

Description of health condition studied
prevent heart attack and stroke in people with a history of heart disease,
ICD-10 code
Z79.02
ICD-10 code description
Long term (current) use of antithrombotics/antiplatelets

Primary outcomes

1

Description
Plasma concentration of Ticagrelor and its active metabolite, AR-C124910XX
Timepoint
at 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing
Method of measurement
Using High Performance Liquid Chromatography wit MS detector (HPLC/MS)

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group:Ticagrelor 90mg tablet, produced by Actover Co., (IRAN), single dose.
Category
Other

2

Description
Control group: Brilique 90mg tablet, produced by Astra-Zeneca company, single dose
Category
Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Core Research Lab. of ZAUMS
Full name of responsible person
Ebrahim Kord
Street address
Emam Ali Hospital, Salamat Blv., Khalij-e-Fars Highway
City
Zahedan
Province
Sistan-va-Balouchestan
Postal code
9816743111
Phone
+98 54 3329 5664
Fax
+98 54 3329 5665
Email
crl@zaums.ac.ir
Web page address
http://crl.zaums.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Actoverco
Full name of responsible person
Nahaleh Naraghi
Street address
No 58, 8th St, Kouye Nasr St
City
Tehran
Province
Tehran
Postal code
1446863914
Phone
+98 21 4163 7000
Fax
+98 21 4163 7000
Email
info@actoverco.com
Web page address
https://www.actoverco.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Actoverco
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Pars Biopharmacy Research Co.
Full name of responsible person
Ladan Tayebi
Position
Managing Director
Latest degree
Medical doctor
Other areas of specialty/work
Medical Pharmacy
Street address
1st floor, Saeidi Dd end, Palestin Ave.
City
Tehran
Province
Tehran
Postal code
1416673971
Phone
+98 21 8895 6061
Fax
+98 21 8896 9958
Email
l.tayebi@parsbiopharmacy.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Pars Biopharmacy Research Co.
Full name of responsible person
Ladan Tayebi
Position
Managing Director
Latest degree
Medical doctor
Other areas of specialty/work
Medical Pharmacy
Street address
1st floor, Saeidi Dd end, Palestin Ave.
City
Tehran
Province
Tehran
Postal code
1416673971
Phone
+98 21 8895 6061
Fax
+98 21 8896 9958
Email
l.tayebi@parsbiopharmacy.com

Person responsible for updating data

Contact
Name of organization / entity
Pars Biopharmacy Research Co.
Full name of responsible person
Ladan Tayebi
Position
Managing Director
Latest degree
Medical doctor
Other areas of specialty/work
Medical Pharmacy
Street address
1st floor, Saeidi Dd end, Palestin Ave.
City
Tehran
Province
Tehran
Postal code
1416673971
Phone
+98 21 8895 6061
Fax
+98 21 8896 9958
Email
l.tayebi@parsbiopharmacy.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...